Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease - Wikidata - awgldk - TriplyDB

Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

http://www.wikidata.org/entity/Q36713101

about

Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease Drug and gene delivery across the blood-brain barrier with focused ultrasound Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound.The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra.Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.Adeno-associated virus vectors and neurological gene therapy.Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.Neurotrophic factor therapy for Parkinson's disease: past, present and future.Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.How does conserved dopamine neurotrophic factor protect against and rescue neurodegeneration of PC12 cells?Plasma membrane temperature gradients and multiple cell permeabilization induced by low peak power density femtosecond lasers.Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population.Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats.Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.Gene Therapy for Parkinson's Disease, An Update.Emerging Roles for Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Pancreatic Beta Cells and Diabetes

P2860

Q27320553-76CC16EA-F10B-4654-A4FE-742B58131F50 Q28080611-34196977-77AA-4B06-B442-DC66D49BF06B Q30277809-36161D2F-8AAE-47F7-9691-AA941C15E6CF Q30376382-B3D9D130-3D5C-4E25-934D-CEF6C762BD55 Q34768987-45CFA167-C3D2-4675-99BC-8CC71B4136DC Q37516424-8B652262-D286-4528-AAB3-D6042C5CDEE7 Q37654138-7F5D4331-B92F-4656-A8F1-1DFC6C6F22C5 Q37693952-74175815-8D1C-405F-9EFF-E8B7D1C9C58C Q38190041-7C184F93-79BD-4A55-B02C-4B18268377D3 Q38194531-33D6CAD5-3671-4086-BDF1-A926918300AB Q38495722-717E33B0-FFDD-4BCE-B5D6-0A4108DECE89 Q38569775-C471D08E-2917-4D84-BE0E-839575D21CD0 Q38602888-94E86EEE-95A9-486E-8A2F-704D24E3D42C Q38881852-EA3163F7-9849-48E9-B38A-9C94B2E5988C Q38942851-CE83367B-5B28-40ED-9C12-FF103F161E33 Q39139260-78EE8109-7316-4FF2-8BB7-37F7CB2F0AA5 Q39197908-5A374537-581D-453A-83DD-89042F6AE049 Q40121209-7FFB72B1-5E7E-456F-A202-2A719241D849 Q41429895-09BC5B70-2497-49E0-96CC-085DBA4FC4E8 Q41683406-8C370E44-B1DB-4E11-B9BF-1E8CA42EFF2F Q47141045-4E080FED-22E2-4E57-BBFF-ABC884B7B4EA Q47852599-1D55F33C-FDFD-49B4-854D-286316E7962D Q50736097-8013FB86-B071-4BF1-92E7-B1AEC3D0DAEA Q55418920-7B176EB6-4F78-4BFB-B790-F52A0A0E3ECF Q58554232-4032157B-1822-4DB4-AF5A-F4EE3A6D0439

P2860

Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

http://www.wikidata.org/entity/Q36713101

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@ast

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@en

type

label

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@ast

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@en

prefLabel

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@ast

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@en

P1433

Q36713101-18EFC881-8450-4DFD-9456-27EBBCF44AC6

P1476

Q36713101-8DE7E1D9-D807-45DB-9D42-DC278AE59A75

P2093

Q36713101-2DB6AC18-5E3D-41AE-AA13-76B9C306CE2B

Q36713101-2F3DE3EC-98D7-4D51-8E10-7A88007CB245

Q36713101-30C8E8DB-B87A-40B0-BF47-DF8DCFE152CA

Q36713101-52772B02-16D6-4F03-9B40-79309461B3A3

Q36713101-68722F95-6D6A-4AAC-9303-8675D74E761C

Q36713101-A798A359-07F8-4C40-B965-C2632F2A08E1

Q36713101-EBFABC46-C5EC-46BD-8047-0FD2F047B3B1

Q36713101-FA2F31B8-6B53-4B82-8D8A-DD4C5E25C3FC

P2860

Q36713101-0CD3912C-1206-42A9-9974-AA66A9966B5F

Q36713101-18C2AFF1-F8C8-4E60-BFA3-C8D5837688FA

Q36713101-19F96A7D-5347-406B-BFB7-FAB393835584

Q36713101-1C9C692D-5C44-4084-AC0C-DD392CF1A076

Q36713101-206516FC-BFEA-408F-AB09-F2B94AB2AC61

Q36713101-208CD107-67D1-4BB2-8651-1FD98F9336F9

Q36713101-21014E8A-B95E-48DF-A08E-62FEBFD60F81

Q36713101-2153FD72-0A7E-4A20-BB9B-87F975E3F9BA

Q36713101-2A7661BD-9B14-4647-AA48-ECF75C5F89BF

Q36713101-2BCB50F6-714D-4C1C-82D5-35885A06F8B8

P304

Q36713101-A5DF9D0E-598F-46B6-881F-9859B0532978

P31

Q36713101-3CC03376-5333-4175-BC8F-3633256FECB1

P356

Q36713101-E24C416E-41D8-4236-BA6A-E4BFB2A6A9C7

P433

Q36713101-5FBC1D39-A1D8-4554-B973-31B6773D50F3

P478

Q36713101-4DC3FAE4-3F49-4B2C-BCDE-4369CD632540

P50

Q36713101-4CAE7323-4D5F-474C-A4B0-3383BBCBAE38

Q36713101-D18AFF94-B201-485F-81BC-8A2E294144D3

Q36713101-D3F55C86-19F7-4562-9D4E-C350BF39D659

P577

Q36713101-593187AE-16D3-471C-AAF9-6E519A2B3458

P5875

Q36713101-746632BB-44D1-4BE8-B2FE-0E1DC036DF3A

P698

Q36713101-3AEE8296-300F-4AC5-ABE4-0BFB57D604C4

P921

Q36713101-6E40E231-DF9F-4457-84AD-26D601509EB2

Q36713101-F2B088D6-29DE-481B-B7E5-FA5374EDB957

P932

Q36713101-02AE6088-221D-47C4-8F16-C5895945CA48

P356

P1433

Brain and Behavior

P1476

Gene therapy with AAV2-CDNF pr ...... t model of Parkinson's disease

@en

P2093

Atso Raasmaja

http://www.w3.org/2001/XMLSchema#string

Emilia Galli

http://www.w3.org/2001/XMLSchema#string

Johan Peränen

http://www.w3.org/2001/XMLSchema#string

Liina Lonka-Nevalaita

http://www.w3.org/2001/XMLSchema#string

Mart Saarma

http://www.w3.org/2001/XMLSchema#string

Päivi Pulkkila

http://www.w3.org/2001/XMLSchema#string

Raimo K Tuominen

http://www.w3.org/2001/XMLSchema#string

Tuulia Tamminen

http://www.w3.org/2001/XMLSchema#string

P2860

Functional recovery in parkinsonian monkeys treated with GDNF

The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional

Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Has a Unique Mechanism to Rescue Apoptotic Neurons

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

Crossroads in GDNF therapy for Parkinson's disease

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

P304

75-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BRB3.117

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Pekka T. Männistö

Merja H Voutilainen

P577

2013-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236084510

http://www.w3.org/2001/XMLSchema#string

P698

23532969

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3607149

http://www.w3.org/2001/XMLSchema#string